Portfolio Update: October 2026 + Q3 Earnings outlook
Calumet and other refiners sold off alongside AI names, but the RIN thesis for renewable fuel earnings remains unchanged ahead of Q3 results.
Calumet and other refiners sold off alongside AI names, but the RIN thesis for renewable fuel earnings remains unchanged ahead of Q3 results.
Lots of financials like insurance brokers, banks, retail brokerages getting smoked on Muse / agentic concerns / cash sweeps / wealth mgmt? $SCHW, $LPLA, $RJF all getting crushed along with all of insurance Looks like sell first, think later is back https://t.co/pvWN2aytg3
$MDT $MMED exchange offer an interesting special sit… Own shares of MDT and swap for MMED at 7% discount Odd lot provision for 99 shares held too High enough share price to be worthwhile ($90+ MDT price works out to $600+ profit in a few weeks time)
$LDOS looks interesting to me. They provide a variety of government services including healthcare, intelligence, defence and homeland security stuff. Currently overearning due to a VA healthcare contract that will be renegotiated lower going into 2027. The market has sold them
Know fins are selling off today, but the $JEF underperformance since Radiant World feels like perception <> reality. We literally just saw this movie with First Brands: scary headline, fears of a much bigger balance-sheet problem, then the actual exposure comes into focus. Fool me once…
$SRAD is explicitly mentioned in $META Muse source code & technical documentation - although functionality does not appear to have been turned on yet I believe Meta will expand their relationship with Sportradar https://t.co/OS10T9268i https://t.co/MzTsyf3WV0
One of the better parts about Muse taking off like this for $META is that Watermelon can now be a total flop and no one will care. The bar has now been essentially removed. Who cares if $META can’t make a frontier coding model anymore if they win consumer? If Watermelon does exceed expectations, that’s pretty much just house money
@310Value reminder that $APG pfd A stock, by which the holders get paid hedge fund-like incentive comp based on year end share price, will be converted at year end. Management/board are well incentivized to do everything they can to juice the stock price into year end.
Portfolio returned over 15% in October, lifting cumulative gains to 103.5%, while adding 3i Group and increasing Floor & Decor and…
Agnico Eagle expects low-end 2026 guidance despite Barnat setbacks, while Hope Bay, Upper Beaver and Odyssey support production above 4…
Arbor Realty Trust’s dividend suspension is presented as creating $60 million of liquidity, raising questions about its ability to meet…
Amazon reported Q3 2026 net sales up 12% year over year to $201.9 billion, narrowly below the $202.3 billion consensus estimate.
AAOI, Lumentum and Coherent 800G ramps, NVIDIA Rubin timing, and AMD, Intel and Arm server CPU demand frame an expert call on AI…
FTAI’s Aerospace Products margin rebounded to 31% as CFM56 module output rose, while Power deposits and contracted deliveries fund its 2027…
Microsoft’s Azure grew 48% as AI monetization accelerated, but doubled CapEx, largely for CPUs and GPUs, reduced quarterly free cash flow…
Life360 has fallen 60% despite 40% revenue growth, 100 million monthly users and profitability, as its family-safety subscriptions and…
Anthropic’s revenue growth slowed from 147% in Q2 to 45% in Q3, raising questions about AI capital spending as Amazon holds capex flat.
American Tower could gain $1.13 to $3.54 in AFFO per share if Starlink accesses 80,000 U.S. cell sites and becomes a fourth major tenant.
T · short AT&T’s stalled deleveraging and share repurchase case has prompted a bearish turn on the telecom stock.
Alphabet trades below 20x forward earnings after a 30% drop from 2026 highs, while 31.8% operating margins and AI capex frame the…
Chevron’s Q3 revenue rose 35% to $65.2 billion and EBITDA 75% to $20.2 billion, while production trailed guidance and refining margins…
AstraZeneca reported $16.2 billion Q3 revenue, up 7%, as oncology grew 17% and Farxiga fell 25% after US generics.
Sanofi raised FY26 guidance after Q3 sales grew 14.3% at constant currency, led by 34.8% Dupixent growth; vaccines declined 6.6%.
SK hynix's U.S. ADR trades at a valuation discount despite AI-driven memory demand, with 50% of 2027–2028 capacity under long-term…
Bloom may have reopened imports of scandium-containing components from China to the United States, according to new trade data.
Amazon projects AWS growth above 40% through 2028 while funding a $220 billion capex plan with rising debt and an $80 billion equipment…
Markel spent $315 million repurchasing shares in Q3 as Thrive agreed to buy ADT for $7.6 billion and Hasbro cited rising adult toy demand.
Alphabet's Google Cloud operating income more than tripled to $11.1 billion, while EPS fell 26% on a $2.76 billion SpaceX paper loss.
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.